Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2008 Earnings Presentation
19 slides from Novo Nordisk A/s Class B's earnings presentation, Apr 30, 2008
Slide 1: A focused healthcare company
Conference call 30 April 2008 A focused healthcare company First three months of 2008 conference call 30 April 2008, 13.00 CET, 12.00 UK time, 7.00 New York time
Slide 2: Agenda
Conference call 30 April 2008 First three months of 2008 Slide no 1 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results (Jesper Brandgaard, CFO) • Outlook for 2008 (Jesper Brandgaard, CFO) •
Slide 3: Forward-looking statements
Conference call 30 April 2008 First three months of 2008 Slide no 2 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2007 and Form 20-F both expected to be file
Slide 4: Highlights
Conference call 30 April 2008 First three months of 2008 Slide no 3 Highlights Sales development: • Sales of modern insulins increased by 33% (25% as reported) • Sales of NovoSeven® increased by 10% (2% as reported) • Sales of Norditropin® increased by 17% (12% as reported) • Sales in North America
Slide 5: Key products continue to drive growth
Conference call 30 April 2008 First three months of 2008 Slide no 4 Key products continue to drive growth – first three months of 2008 Sales as reported Growth analysis HRT Norditropin ® -5% Local currencies Growth Share of +12% growth 4% 8% Modern insulins 33% 70% Diabetes care NovoSeven® +10% Huma
Slide 6: Modern insulins
Conference call 30 April 2008 First three months of 2008 Slide no 5 Modern insulins World market share of total segment Modern insulin sales as reported 50% Levemir® NovoRapid® DKK 0.8bn NovoRapid® NovoMix® +70% DKK 1.8bn 40% Levemir® +15% 21% 30% 46% NovoMix® 20% DKK 1.2bn 33% +18% 10% 0% February
Slide 7: A continued increase in modern insulin market share
Conference call 30 April 2008 First three months of 2008 Slide no 6 A continued increase in modern insulin market share IMS world modern insulin Modern insulin penetration market shares, volume 70% Novo Nordisk 60% Eli Lilly Sanofi-Aventis 53% 50% Modern insulin 23% 40% 30% Human insulin 20% 10% 0%
Slide 8: NovoSeven sales development
Conference call 30 April 2008 First three months of 2008 Slide no 7 NovoSeven® NovoSeven® sales development Key observations • Growth in the first quarter of 1,600 10% in local currencies and 2% 9% A GR : as reported 1,400 C 1,200 • North America and International DKK million Operations main contrib
Slide 9: Norditropin sales development
Conference call 30 April 2008 First three months of 2008 Slide no 8 Norditropin® Norditropin® sales development Key observations • Growth in the first quarter of 17% in local currencies and 12% 1,000 % as reported 900 : 12 A GR 800 C • North America main contributor to growth with more than 50% DKK
Slide 10: Sales by region
Conference call 30 April 2008 First three months of 2008 Slide no 9 Sales by region - first three months of 2008 Sales as reported Growth analysis Japan & Oceania +3% Europe Local Growth Share of +3% currencies growth 9% International Europe 4% 12% Operations North America 21% 48% +24% 20% 38% Inter
Slide 11: Levemir reinforces modern insulin market leadership in Europe
Conference call 30 April 2008 First three months of 2008 Slide no 10 Levemir® reinforces modern insulin market leadership in Europe… Share of total modern insulin Novo Nordisk’s share of long- sales in Europe acting modern insulin in Europe 30% 80% Novo Nordisk Eli Lilly 70% Sanofi-Aventis 25% 60% 2
Slide 12: … and total market leadership in the US
Conference call 30 April 2008 First three months of 2008 Slide no 11 … and total market leadership in the US US total insulin market Novo Nordisk’s share of long- share development acting modern insulin in the US 80% 10% 70% Novo Nordisk 9% Eli Lilly 60% Sanofi-Aventis 8% 7% 50% 6% 40% 5% 30% 4% 3%
Slide 13: Development portfolio – diabetes
Conference call 30 April 2008 First three months of 2008 Slide no 12 Development portfolio – diabetes Compound Type Indication Phase NovoMix® 50 Modern insulin Type 1+2 Launched in Europe, filed in the US NovoMix® 70 Modern insulin Type 1+2 Launched in Europe, filed in Japan PrandiMet® OAD Type 2 Fi
Slide 14: Development portfolio – haemostasis
Conference call 30 April 2008 First three months of 2008 Slide no 13 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Heat-stable formulation Approved in Europe, filed in the US NovoSeven® Trauma Phase 3 NN1731 Fast-acting factor VIIa analogue Phase 2 NN71281 Long-acting fact
Slide 15: Development portfolio - other biopharmaceuticals
Conference call 30 April 2008 First three months of 2008 Slide no 14 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® Low Dose Hormone replacement therapy Launched in the US, filed in Europe1 Vagifem® Low Dose Hormone replacement therapy Filed in the US, phase 3
Slide 16: Financial results
Conference call 30 April 2008 First three months of 2008 Slide no 15 Financial results DKK million Q1 2008 Q1 2007 % change Sales 10,614 9,818 8 Gross profit 8,201 7,498 9 Gross margin 77.3% 76.4% Sales and distribution costs 2,975 3,048 (2) Percent of sales 28.0% 31.0% Research and development cost
Slide 17: Currency development
Conference call 30 April 2008 First three months of 2008 Slide no 16 Currency development Spot rates Quarterly average Annual average 650 Annual impact on operating USD/DKK 600 profit of a 5% movement in currency (DKK million) 550 2008 USD 470 500 USD-related 100 JPY 140 450 GBP 85 Q106 Q206 Q306 Q4
Slide 18: Outlook 2008
Conference call 30 April 2008 First three months of 2008 Slide no 17 Outlook 2008 • Sales growth expectations: Key currency rates • Between 10-13% in local currencies DKK 2007 2008 Current per 100 average average rate* • Around 6 %-points negative currency impact USD 545 492 479 • Operating profit g
Slide 19: Investor information
Conference call 30 April 2008 First three months of 2008 Slide no 18 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its ADRs Novo Allé, DK-2880 Bagsværd are lis